Sakar Healthcare reported 42% YoY revenue growth in Q4FY26, driven by new market authorizations and strong demand.
EBITDA surged 67% YoY to ₹2,624 lakhs with margins at 37%, reflecting operating leverage and cost management.
Profit after tax increased 91% YoY to ₹1,102 lakhs, indicating enhanced profitability and efficiency gains.
The company completed over 60 business contracts and received multiple regulatory approvals for oncology products.